Cancer Research Donation with The Hope Foundation
The Hope Foundation funds cancer research, education, and patient advocacy for SWOG, one of the NCI’s National Clinical Trials Network (NCTN) groups.
Related Articles
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer | NEJM
Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder canc…
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer | NEJM
Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder canc…
No Shortage of Important Results | SWOG
Here are two from the past week – a risk prediction model presented at the 2024 ASCO Quality Care Symposium that may help us improve the care…
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer | NEJM
Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder canc…
Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer | NEJM
Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder canc…
Learning Even More from Our Patients | SWOG
But there’s plenty of room for improvement in how we do correlative science. The chairs of the six adult and pediatric NCTN cooperative groups have…
S1712 Supports Adding Ruxolitinib to TKIs for CML | SWOG
Results are being presented at the European School of Haematology’s 26th Annual John Goldman Conference on Chronic Myeloid Leukemia, to be held in Prague, September…
Risk Model IDs Trial Patients at Highest Risk for Acute Care Use | SWOG
Determining which patients are at significantly higher risk could inform interventions to reduce the need for such visits, improving care quality and reducing costs. The…
S1712 Reports Better Response Rate in CML | SWOG
Kendra L. Sweet, MD, of the Moffitt Cancer Center, who led the study, will deliver the results at the conference’s first scientific session, one reserved…
Clinical Utility of Molecular Tumor Board Review for Identification of Possible Germline Pathogenic Variants on Tumor Next-Generation Sequencing Reports | JCO Precision Oncology
PURPOSE Tumor next-generation sequencing (NGS) testing identifies possible germline pathogenic variants (PGPVs), creating a dilemma for appropriate recognition, triage, and management. The objective of this…